cyrilzakka/clinical-trials huggingface dataset:
Method for BAdge-dosi Monitoring of X-ray Exposure Values in Operating Theatre Surgery

Surgical procedures involving X-rays in the operating room have increased in recent years, thereby increasing the exposure of operating room staff to ionizing radiation. An individual dosimeter makes it possible to record the radiation exposure to which these personnel are exposed. However, it has been noticed that these dosimeters are not thoroughly worn, consequently the radiation doses recorded are not reliable.

In order to increase the proportion of dosimeters systematically worn in the operating room, we study the impact of the association of the passive dosimeter with the hospital access badge (forming the Badge-Dosi). A first pilot study was carried out at Tours University Hospital showing the effectiveness of this concept. With the present study, we carry out a multicenter study. Our hypothesis is that the Badge-Dosi allows a significant increase of dosimeter use in the operating room, which improves the reliability of the monitoring of personnel.


Eligibility Criteria:
Inclusion Criteria:

TEST group :

* People working in the operating room at least 80% of the time (excluding people working less than 80% of the time).
* Have been monitored by a delayed-reading dosimeter for at least 1 year.
* Carry an access card (i.e. be the holder).

LIFE group :

* Person working in the same centre as the people in the TEST group.
* Person not exposed to radiation at their workstation
* Holder of an access card

HOME group :

- Person working in the same centre as people in the TEST Group and live near the center

Exclusion Criteria:

For all Groups :

* Person objecting to data processing
* Interns/externs/non-permanent staff likely to change jobs during the study period
* Person who had a nuclear medicine examination within 15 days before the start of the study
* Anyone who had internal vectorised therapy with iodine-131 or Lu-177 within 30 days before the start of the study.
Trimetazidine in Pulmonary Artery Hypertension

Pulmonary artery hypertension (PAH) is a chronic and progressive disease that affects 15 persons per million. Although current therapy has improve disease prognosis, PAH still has a poor survival, with a median survival of 2.8 years after diagnosis. In the last few years new key elements in PAH pathogenesis have been discovered, such as the role of metabolism in disease onset and progression. In fact, PAH pulmonary smooth muscle cells switch into a glycolytic phenotype which resembles the metabolism of cancer cells. The investigators hypothesis is that "fatty acid oxidation inhibition reverts the PAH adverse phenotype by restoring mitochondrial function and morphology, decreasing proliferation and restoring apoptosis susceptibility in pulmonary smooth muscle cells "


Eligibility Criteria:
Inclusion Criteria:

* PAH patients belonging to the following subgroups of the updated Dana Point Classification Group 1

  1. Idiopathic PAH
  2. Heritable PAH
  3. Drug or toxin-induced PAH
  4. PAH associated with connective tissue disease
  5. PAH associated to congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair
  6. PAH associated to HIV infection
* Documented hemodynamic diagnosis of PAH by right ventricular catheterization performed any time prior to screening
* Signed informed consent

Exclusion Criteria:

* Patients belonging to the subgroups of the updated Dana Point Classification Group I not listed in the inclusion criteria
* Patients belonging to the groups 2-5 of the updated Dana Point Classification Group
* Moderate to severe chronic pulmonary obstructive disease
* Documented left ventricular dysfunction
* Severe renal impairment (Serum creatinine \> 2.5 mg/dL)
* Patients who are receiving or have been receiving any investigational drugs within 1 month before the baseline visit
* Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements
* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
* Life expectancy less than 12 months
* Females who are lactating or pregnant or those who plan to become pregnant during the study
* Known hypersensitivity to any of the excipients of the drug formulation
A Prospective,Randomised, Open Label Study for Comparison of the Incidence and Severity of Postoperative Sore Throat (POST) Using C-MAC Video Laryngoscope and Traditional Macintosh Laryngoscope for Intubation

The aim of this study is to compare the incidence of postoperative sore throat after intubation with two different types of laryngoscopes.

Postoperative sore throat is a well known complication after endotracheal intubation. One of the major contributing factors is trauma associated with laryngoscopy. With decreased force applied to visualise cords, video laryngoscopes should decrease the incidence of postoperative sore throat. In this study we compared the incidence and severity of postoperative sore throat when laryngoscopy was done using c-mac video laryngoscope D-blade( group V) versus Macintosh laryngoscope (Group M). Method: Fifty four American society of Anaesthesiologists (ASA) 1\&2 patients between age 18-60 years , undergoing laproscopic surgeries of short duration were included in this study and laryngoscopy was done with Macintosh laryngoscope in M group and with C MAC video laryngoscope D blade in V group. Patients were followed up 2hours, 6hours, 12hours and 24hours in postoperative period to see postoperative sore throat and hoarseness of voice .

Eligibility Criteria:
Inclusion Criteria:

* Age more than 18 years
* American society of Anaesthesiologists(ASA)1 and 2
* Mallampati (MPC) grading 1 and 2
* laparoscopic cholecystectomy and appendectomy
* Surgeries of short duration(\<2hour)

Exclusion Criteria:

* Patients refusing to give consent
* Pregnant and lactating patients
* Patients with severe co-morbidities requiring postoperative ventilatory support
A Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout

The purpose of this study is to determine the efficacy and safety of recombinant anti-IL-1β humanized monoclonal antibody injection in Chinese participants with acute gout.

Study SSGJ-613-AG-III-01 is a phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled, parallel-group study examining the effect of recombinant anti-IL-1β humanized monoclonal antibody injection versus compound betamethasone injection in Chinese adult patients with frequent flares of acute gouty arthritis who are contraindicated, intolerant, or lack efficacy to non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine. The entire treatment period is 48 weeks, consisting of a double-blind treatment period of 24 weeks and an open treatment period of 24 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Must be 18 Years to 75 Years, both male and female.
* BMI ≤35 kg/m2.
* Meeting the American College of Rheumatology (ACR) 2015 criteria for the classification of acute arthritis of primary gout.
* History of ≥ 3 gout flares within the 12 months prior to study randomization.
* Onset of current acute gout flare within 4 days prior to study screening.
* Screening pain intensity of the Target Joint ≥ 50 mm on the 0-100 mm VAS.
* Contraindicated, intolerant or lack efficacy to NSAIDs and/or colchicine.
* Accept uric acid lowering treatment according to the requirements of the protocol.

Exclusion Criteria:

* Gout caused by radiotherapy/chemotherapy, lead, organ transplantation, tumors, etc.
* Evidence/suspicion of infectious/septic arthritis, or other acute inflammatory arthritis.
* Presence of severe renal function impairment.
* Intolerance of subcutaneous and intramuscular injection.
* Known presence or suspicion of active or recurrent bacterial, fungal or viral infection at the time of enrollment.
* History of malignant tumor within 5 years before screening.
* Live vaccinations within 8 weeks prior to the start of the study.
* Use of forbidden therapy.
Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis

The purpose of this study is to evaluate the ability of contrast enhanced carotid ultrasound to serve as an indicator of disease activity in patients with Takayasu's arteritis or Giant Cell arteritis and to determine if patients with active arteritis have a thickening of their blood vessel walls compared to healthy people of the same age and gender.

Takayasu's arteritis and Giant Cell arteritis are chronic, relapsing diseases of the large arteries which can lead to significant narrowing of the arteries through episodes of inflammation within the artery walls. The changes in the vessel walls will be determined by an ultrasound test looking at and measuring: carotid vessel wall changes called carotid Intimal-Media Thickness (cIMT) and the presence of new blood vessels (neovascularization) using a contrast agent. Ultrasound findings will be correlated with markers of inflammation in the blood, findings from other radiology studies (such as MRI) already ordered as part of routine clinical care, and physical exam findings and symptoms of consistent with disease activity. 15 arteritis patients and 5 healthy controls will be recruited.

Eligibility Criteria:
Inclusion Criteria:

* Male and female patients \>18 years
* Diagnosis of Takayasu's arteritis or giant cell arteritis
* Suspicion of common carotid involvement on the basis of physical examination (cervical bruit), carotidynia, documented CCA involvement on an imaging study (MRA, CTA, or ultrasound), or documented upper extremity large vessel involvement on an imaging study (MRA or CTA or ultrasound).
* Ability to provide informed consent

Exclusion Criteria:

* Prior stroke, carotid surgery or angioplasty
* Pregnant (or trying to become pregnant)
* Nursing
* Known or suspected cardiac shunt
* Documented hypersensitivity to the contrast agent
* Severe pulmonary hypertension or unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias, or respiratory failure)
Assessment of Disability Compensation With the C-LEG COMPACT 2 Knee (Ref. 3C60 et 3C60=ST)

Moderately active amputees may have lost their limb due to diabetes, vascular conditions, trauma, tumour or congenital causes. These amputees currently cannot benefit from having a computerised knee because of the performance criteria associated with being given one. However, these amputees have a very high risk of falling because they use a non microprocessor controlled knee joint (NMPK) and because their physical ability, associated disability and persistent contralateral leg weakness do not allow them to compensate for a balance deficit. These amputees restrict how much they move around and their participation because of their instability and elevated risk of falling.

The objective of the study is to evaluate the effect of the 3C60 knee, a microprocessor-controlled knee joint for external leg prosthesis, on the reduction in the risk of falling after three months in moderately active persons with leg amputation above knee or knee disarticulation.

The patient will be evaluated after one month of using his/her usual non micropressor controlled knee joint (NMPK). After fitting of the 3C60, the patient will undergo at least five rehabilitation sessions, adapted to his/her individual needs, so that he/she knows how to use the device and is ready to go along with the planned testing.

After the trial with the 3C60 knee, the patient will again be fitted with his/her non microprocessor controlled knee joint (NMPK) and will be required to undergo one rehabilitation session to regain his/her walking abilities.

Eligibility Criteria:
Inclusion Criteria:

* Person with leg amputation above knee or knee disarticulation with stabilized residual limb
* Person who are currently fitted with a prosthesis using a non-microprocessor controlled prosthetic knee
* Person with a high risk of falling, which is defined as a TGUG test score of more than 19 seconds
* Person who moves around within buildings other than one's residence, such as moving around other people's homes, other private buildings, community and private or public buildings and enclosed areas, moving throughout all parts of buildings and enclosed areas, between floors, inside, outside and around buildings, both public and private
* Person who moves around outside the home and other buildings, such as walking and moving around close to or far from one's home and other buildings, without the use of transportation, public or private, such as walking for short or long distances around a town or village, walking or moving down streets in the neighbourhood, town, village or city; moving between cities and further distances, without using transportation
* Person with a daily walking distance greater than 300 m

Exclusion Criteria:

* Persons using underarm crutches or walkers
* Persons under 18 years of age
* Persons who weigh more than 125 kg
* Pregnant women
* Persons in an emergency situation
* Persons who cannot personally provide their consent
* Persons who are not available to follow the entire study protocol
Exercise as a Buffer Against Stress-induced Overeating

The purpose of this study is to examine the psychological benefits of chronic exercise as well as the effects of exercise training on eating behaviors and stress-induced overeating in overweight and obese women. Participants will be randomized to an 12-week exercise condition or a delayed exercise condition. Assessments will occur at baseline, 6 weeks, and 12 weeks and will include answering surveys in real-time using smartphones, several assessments of eating behaviors and dietary intake, and questionnaire measures of factors which could mediate the relationship between exercise and eating. Participants will be compensated for completing assessments and for adherence to the exercise protocol.


Eligibility Criteria:
Inclusion Criteria:

* Female
* 18-60 years of age
* BMI 25 to \<40 kg/m2
* Physically inactive (\<60 min/week of physical activity)
* Must own a smartphone
* Must be willing to receive and respond to text message prompts for 14 days at baseline, 6 and 12 weeks

Exclusion Criteria:

* Shift workers
* Individuals who do not endorse stress-eating
* Recent weight loss or current enrollment in a weight loss program
* Women who are pregnant or plan on becoming pregnant in the next 6 months
* Any medical condition that would limit participation in physical activity
* Diabetes
* Inability to walk without an assisted device
* Inability to meet exercise recommendations
* Failure to adequately complete all baseline assessment measures
The Effect of Distant Reiki Application on Pain, Functional Status and Sleep Quality

Rheumatoid Arthritis (RA) is a chronic, multisystemic, progressive autoimmune disease characterized by joint destruction in synovial tissue, causing joint swelling, pain and morning stiffness. It is estimated to affect 0.1%-2% of the world's adult population and more women than men. RA limits individuals' work, social, and home lives and functional capacities. Patients commonly experience pain and accompanying sleep problems. Interventions for these problems and symptom management are important. In this regard, this study was planned to examine the effect of distant reiki application on pain, functional status and sleep quality in rheumatoid arthritis patients.


Eligibility Criteria:
Inclusion Criteria:

* Being over 18 years old,
* Not having a communication problem,
* Receiving outpatient treatment from the clinic where the research was conducted,
* To have the physical and cognitive competence to answer the data collection forms,
* Not having received body-mind therapy (yoga, reiki, meditation, etc.) in the last six months,

Exclusion Criteria:

* individuals who have done reiki therapy before
* Being under 18 years old,
* Hearing and speaking problems that prevent communication,
* Participating in yoga, reiki, meditation practices in the last 6 months,
* Individuals with cognitive and severe psychiatric problems who cannot answer the survey questions
Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer

This is an open-label, randomized trial, it compares the efficacy and safety between apatinib combined chemotheray and chemotherapy for adjuvant treatment of esophageal cancer


Eligibility Criteria:
Inclusion Criteria:

* IIA-IIIC phase esophageal squamous cell carcinoma confirmed by histopathology and immunohistochemistry.
* R0 resection has been performed at least before 4 weeks.
* ECOG PS score: 0-1 points.
* Estimated survival time: at least 12 weeks.
* No radiotherapy, chemotherapy or molecular targeted therapy before.
* Main organs are functional, which meet the following criteria:

Blood Routine:

HB≥90 g/L（No blood transfusion within 14 days）, ANC≥1.5×109/L, PLT ≥80×109/L. Biochemical examination： ALB≥30g / L（No blood transfusion within 14 days）, ALT\<2ULN； AST\<2ULN TBIL≤1.5ULN； Plasma Cr≤1.5ULN；

* Volunteer with signed informed consent form, good compliance and good follow-up cooperation.
* Patients who the investigator believws they can benefit.

Exclusion Criteria:

* Those who have had other malignant tumors in the past or at the same time.
* Pregnant or lactating women.
* Patients with grade-II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTC interval ≥ 450 ms) and cardiac dysfunction according to NYHA criteria III to IV. Cardiac color Doppler examination: LVEF (left ventricular ejection) Score) \<50%.
* Have clear gastrointestinal bleeding concerns (such as local active ulcer lesions, fecal occult blood ++), and a history of gastrointestinal bleeding within 6 months.
* Have a history of mental illness or psychotropic substance abuse.
* Patients who have participated in other drug clinical trials within 4 weeks.
* According to the investigator's judgment, patients who are at a risk or have accompanying disease.
* Patients who believe that they are unsuitable for inclusion.
Cognitive Enhancement and Relapse Prevention in Cocaine Addiction

For this project, the investigators are interested in exploring a new way to extend and maintain drug abstinence in people who are addicted to crack cocaine. This study will combine a medication called D-Cycloserine (DCS) and weekly cognitive behavioral therapy (CBT) to assess whether the combination will enhance people's ability to stay clean (drug free) for longer periods of time.

One of the greatest risks for drug relapse is drug craving. Oftentimes drug craving occurs when a person is confronted with stressors and reminders of past drug use behavior. DCS has been shown to enhance the learning of new information. By administering DCS prior to learning new techniques such as how to cope with drug craving and drug-use reminders, it is possible that patients can be more successful at living a drug free life for a longer period of time.

In addition to exploring this model behaviorally, the investigators will explore changes that may occur in the brain before and after the therapy/medication intervention. A technique called MRI (Magnetic Resonance Imaging) will be used to identify areas of the brain that are being activated during an attention task. Areas of neural activation will be assessed at study entry, end of therapy (4-week endpoint) and one month following completion of the treatment program.

Primary Hypothesis:

Enhancing glutamatergic neurotransmission with DCS facilitates CBT-related relapse prevention by potentiating the behavioral and neural representation of the diminished drug motivation associated with cocaine cues.

Specific Aims:

1. Determine if the short-term oral administration of DCS relative to placebo prior to CBT sessions facilitates cocaine abstinence and functional recovery, and reduces cocaine craving in treatment-seeking cocaine addicts.
2. Determine if DCS administration relative to placebo facilitates CBT-related decreases in the behavioral and neural response to conditioned cocaine cues.

Eligibility Criteria:
Inclusion Criteria:

* Eligible subjects must be cocaine-dependent persons between 18 and 65 years

Exclusion Criteria:

* Any current Axis-I psychiatric diagnosis other than cocaine or alcohol dependence or nicotine use
* Any current or prior neurological disease, history of a major medical illness, or current use of psychotropic medications
* Positive history of loss of consciousness of greater than 10 min
* Significant current or prior cardiovascular disease (hypertension, arrhythmias) that is not medically stable
* History of hospitalization within the previous six months for a medical illness
* Deafness, blindness or other significant sensory impairment.
* Contraindications for D-cycloserine and magnetic resonance imaging.
Effect of Eradication of Helicobacter Pylori on the Dyspeptic Symptoms

Helicobacter pylori eradication and its impact on symptoms in patients with non-ulcer dyspepsia remain controversial . Many studies have examined the effect of H. pylori eradication on dyspeptic symptoms, but the results have been conflicting and inconclusive, with as many studies yielding positive as negative results. Some studies have shown a significant (although weak) symptomatic improvement after H. pylori eradication, and while other yielding negative results. A recent Cochrane review has comprehensively demonstrated that H.pylori eradication therapy has a small but statistically significant effect in H.pylori positive non-ulcer dyspepsia. An economic model suggests this modest benefit may still be cost effective . However it is difficult to reconcile these results in areas with very high prevalence of H. pylori infection such as Pakistan since no such studies have been conducted in developing countries.

The investigators hypothesize that eradication of Helicobacter pylori (H. pylori) leads to a sustained improvement in symptoms of patients diagnosed with H. pylori associated functional (non-ulcer) dyspepsia.


Eligibility Criteria:
Inclusion Criteria:

* Ambulatory adult males and non-pregnant females.
* Dyspeptic symptoms for at least 3 months.
* Normal endoscopic findings.
* H. Pylori positive on testing.

Exclusion Criteria:

* Patients with erosive and non erosive esophagitis.
* Barrette's esophagus.
* Duodenal Ulcer, Gastric Ulcer or gastric erosions.
* Patients with known sensitivity to antibiotics.
* Patients with severe concomitant systemic disease.
* Patients with upper GI surgery except cholecystectomy.
* Females with pregnancy or breast-feeding.
* Malignancy
* Alarm symptoms such as bleeding per rectum, hematemesis, and severe weight loss.